The CHECKMATE-227 trial of nivolumab and ipilimumab presents a potential new frontline chemotherapy-sparing treatment option for patients with PD-L1-positive non-small-cell lung cancer and perhaps, in the future, also for those with PD-L1-negative disease. Indeed, the true predictive value of PD-L1 as well as tumour mutational burden remains to be determined, as neither biomarker segregates clearly with responsiveness.

中文翻译：

---

NSCLC的前线免疫疗法-尾巴的故事。

尼古鲁单抗和伊匹单抗的CHECKMATE-227试验为PD-L1阳性非小细胞肺癌患者以及未来PD-L1阴性患者提供了一种潜在的节约一线新的化疗方案疾病。的确，PD-L1的真正预测价值以及肿瘤突变负担尚待确定，因为两种生物标志物均不能清楚地与反应性分离。